Treatment of Moderate to

Abstract
Treatment of moderate to severe psoriasis often requires systemic therapy, including biologics. Partial response to biologics and relapses are commonly managed with dose escalation. Secukinumab is a relatively new biologic that is currently used to treat moderate to severe psoriasis. There has been no literature published on dose escalation of secukinumab. This article describes the off-label use of a higher dose of secukinumab (450 mg every 4 weeks) instead of the standard dosing (300 mg every 4 weeks) in 2 patients with moderate to severe psoriasis. The first case involves a male patient with a high body mass index (BMI) (≥30 kg/m 2 ) and severe psoriasis who was started on secukinumab at 450 mg following a partial response to treatment with the standard 300-mg dose. His psoriasis significantly improved with the higher dose of secukinumab. The second case discusses a female patient with treatment-resistant psoriasis and a BMI of 31.6 kg/m 2 who initially achieved a complete remission with standard dosing of secukinumab. Later, her psoriasis relapsed and she was dose-escalated to secukinumab 450 mg in an attempt to recapture response, but this dose escalation was unsuccessful. In both cases, there were no adverse events observed with a higher dose of secukinumab. These cases demonstrate that dose escalation of secukinumab (450 mg rather than on-label 300 mg every 4 weeks) may be considered in selected patients with incomplete clearance, particularly for those with a high BMI. However, secukinumab dose escalation may not be as beneficial in patients with loss of efficacy.
Keywords psoriasis, biologics, secukinumab had significant disease. In attempt to improve efficacy, the secukinumab dose was increased to 450 mg subcutaneous every 4 weeks, and the patient was informed of off-label use. At his 3-month follow-up after initiating the higher dose, the patient had improved considerably, stating he was '30% better' than his previous appointment. His PASI was now 6.9 and BSA 7%, and the patient was satisfied with his results ( Figure  2 ). No adverse events were noted during his treatment.
Case 2
A 36-year-old woman with psoriasis and psoriatic arthritis was started on secukinumab after multiple treatments were found to be ineffective or intolerable, including adalimumab, etanercept, methotrexate, apremilast, and cyclosporine. Her psoriasis involved 10% of her BSA (mainly face, feet, hands, shins, elbows, and knees) with a PASI of 13.1. The patient was started on secukinumab with the usual loading dose regimen on September 2015, and dramatic improvement was noted within a week with eventual complete clearance. Her clearance was sustained for 7 months prior to a relapse on March 2016. Initially, there was a minor flare-up on her elbows and knees (1% BSA), and the patient was advised to apply topical calcipotriol and betamethasone dipropionate combination gel over the affected areas. At the next followup, her psoriasis was flaring more, with thick plaques over her knees and elbows with new papules on arms and legs, and the patient reported worsened joint pain. In attempt to recapture the previous efficacy, the secukinumab dose was increased to 450 mg subcutaneously every 4 weeks, and the patient was reexamined 4 months later. No adverse events were observed, but there were no improvements in her psoriasis (~6% BSA) or psoriatic arthritis despite the higher secukinumab dose.
Discussion
Secukinumab is a human monoclonal immunoglobulin G antibody targeting interleukin-17A, the first in its drug class, and has indications for both psoriasis and psoriatic arthritis. 5 For treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the recommended dosage is 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. 4 There has been no literature published on use of secukinumab 450 mg for treatment of psoriasis. Our 2 cases describe the role of secukinumab 450 mg in treating moderate to severe psoriasis and highlight important considerations.
Case 1 highlights the potential benefit of dose adjustment to improve efficacy based on patient factors such as weight. This would be particularly important when dealing with obese patients (BMI ≥30 kg/m 2 ). This case suggests that if a patient is started on secukinumab 300 mg and partial remission has been shown at 16 weeks' follow-up, it might be worthwhile considering a trial of a higher dose of secukinumab before trying a different treatment, especially if the patient is obese. In addition, it has been suggested that it is better to 'exhaust' a given treatment before switching therapies, by using dose escalation or decreasing the interval of treatment, as psoriasis patients appear to become more treatment resistant with exposure to more therapies. 3, 6 Case 2 highlights loss of efficacy with secukinumab over time in a patient with psoriasis who was intolerant or had failed multiple other therapies, including other biologics. In this case, there was no benefit to using the higher dose of secukinumab following relapse after initial remission. Based on this experience, it is recommended to consider other treatment options if loss of efficacy occurs, or some alternative "off-label" optimisation strategies that could be tried include increasing the frequency of secukinumab to 300 mg every 3 weeks (instead of every 4 weeks on-label) or adding other therapies to the 
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secukinumab such as apremilast. Immunogenicity is rarely a problem (<1% over 3 years in clinical trials); therefore, adding methotrexate for this indication is rarely needed.
In the above 2 cases, off-label use of a higher dose of secukinumab did not result in any adverse events. Dose escalation has been shown to be effective for suboptimal treatment responses or loss of efficacy when using other biologic therapies for psoriasis. 2, 3 These cases show that dose escalation of secukinumab (450 mg rather than on-label 300 mg every 4 weeks) may be an effective optimisation strategy for patients with high BMI but was not effective to rescue loss of efficacy. Although the data are limited, clinicians might consider higher-dose off-label secukinumab treatment in selected patients with incomplete clearance.
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